Arch Therapeutics Inc. (ARTH) 0.1753 $ARTH
Arch Therapeutics Announces Positive Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinners
Marketwire - Mon Sep 08, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), announced that an independent third-party research group has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals receiving an anticoagulant medication (i.e. blood thinner). These results were consistent with the results obtained from a recently completed Arch study that showed that AC5 quickly stopped bleeding from surgical wounds created in the livers of rats that had been treated with a clinically relevant dose of the drug heparin.
Arch Therapeutics Will Present at the 2014 Aegis Capital Healthcare Conference in Las Vegas, NV September 10-13th, 2014
Marketwire - Tue Sep 02, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" today announced it will be featured as a presenting company at the 2014 Aegis Capital Healthcare Conference. The presentation will take place at 11:25am PDT on Friday, September 12th at The Encore at Wynn in Las Vegas, NV.
Arch Therapeutics Will Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
Marketwire - Tue Aug 26, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.
Arch Therapeutics Announces Positive Preclinical Data From Its Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinner
Marketwire - Mon Aug 25, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) for potential use in bleeding during surgery, today announced positive data in an initial preclinical study assessing the use of its AC5 Surgical Hemostatic Device(TM) in animals receiving an anticoagulant medication (i.e. blood thinner).
Arch Therapeutics Announces Third Quarter 2014 Results
Marketwire - Wed Aug 06, 6:29AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, today announced financial results for the three and nine months ended June 30, 2014.
Arch Therapeutics Announces Collaboration With University College Cork School of Pharmacy
Marketwire - Tue Jul 22, 7:31AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), has entered into a new collaboration agreement with the University College Cork (UCC) School of Pharmacy in Cork, Ireland, of the National University of Ireland (NUI), focusing on development of hemostasis and sealant products.
Arch Therapeutics Selects BSI as Its European Union Notified Body
Marketwire - Tue Jul 15, 7:31AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has selected the British Standards Institution ("BSI" as its Notified Body. A Notified Body is an organization that has been accredited by a member state of the European Union to assess whether a product meets certain preordained standards to receive a CE Mark designation.
Arch Therapeutics Appoints Richard Davis as Chief Financial Officer
Marketwire - Mon Jul 07, 5:07PM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has appointed Richard Davis as Chief Financial Officer and Treasurer as it continues to expand its team. Mr. Davis, who has worked as a consultant at Arch since April, has started full time in his new role effective today, July 7, 2014. The Company's current Chief Financial Officer and Treasurer, Alan Barber, has resigned from his position effective July 7, 2014 and has become an advisor to the Company.
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23
Marketwire - Mon Jun 16, 7:15AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announces that co-founder and inventing scientist Dr. Rutledge Ellis-Behnke will present his work using AC5(TM) at the Seventh Annual European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on Monday, June 23.
Arch Therapeutics Appoints Chirag Shah, PhD as Vice President of R&D Engineering and Quality Systems and Peter LaCrosse as Chief of Staff
Marketwire - Tue Apr 01, 7:03AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has appointed Chirag Shah, PhD as Vice President of Research and Development Engineering and Quality Systems, effective April 7, 2014, and has appointed Peter A. LaCrosse as Chief of Staff, effective immediately.
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March
Marketwire - Wed Mar 26, 8:03AM CDT
Rutledge Ellis-Behnke, PhD, co-founder and inventing scientist at Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or "the Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, presents his work using AC5(TM) at two scientific meetings.
IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:
Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference
Marketwire - Wed Feb 26, 8:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, MD, is scheduled to present a corporate overview at The Wall Street Analyst Forum Conference in Manhattan at The University Club of NYC on Monday, March 3rd at 12:05 PM EST.
10-Q: ARCH THERAPEUTICS, INC.
Edgar Online - Fri Feb 14, 7:42AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Arch Therapeutics Secures $2.85 Million Private Placement
Marketwire - Mon Feb 10, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care has closed a previously announced private placement to accredited individual and institutional investors (the "Investors" .
OTC Daily Alert Stock Watch - Arch Therapeutics, Inc. (OTCQB: ARTH)
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Arch Therapeutics Announces $2.85 Million Private Placement
Marketwire - Fri Jan 31, 5:00AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce today its private placement to institutional and high net worth investors of an aggregate of 11,400,000 shares of common stock at $0.25 per share, pursuant to the terms of a securities purchase agreement dated January 30, 2014. The private placement is expected to close on or about February 4, 2014, subject to customary closing conditions.
Arch Therapeutics Presents 2014 Milestones During Live Webcast
Marketwire - Wed Jan 22, 10:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., presented its calendar year 2014 milestone targets during a live audio and high-definition video webcast on Wednesday, January 22 at 10:30AM Eastern Time from the Noble Financial Capital Markets' Tenth Annual Equity Conference in South Florida.
Arch Therapeutics to Present Status Update and Milestone Overview at Noble Financial Capital Markets' Tenth Annual Equity Conference
Marketwire - Tue Jan 14, 8:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference in Sandpiper Bay, Florida, on Wednesday, January 22 at 10:30AM Eastern Time.
Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference
Marketwire - Wed Jan 08, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a life sciences company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Terrence W. Norchi, M.D., CEO of Arch Therapeutics will present at The Biotech Showcase(TM) 2014 conference on Monday, January 13th, at 5:00PM PST. Attendees will find the presentation scheduled for "Track C" in the Mission II room at that time. Dr. Norchi's presentation will provide insights into the Company's ongoing activities to commercially develop novel technologies into a suite of new products targeting markets of unmet clinical need.
Arch Therapeutics Announces Positive Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinners
Marketwire - Mon Sep 08, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), announced that an independent third-party research group has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals receiving an anticoagulant medication (i.e. blood thinner). These results were consistent with the results obtained from a recently completed Arch study that showed that AC5 quickly stopped bleeding from surgical wounds created in the livers of rats that had been treated with a clinically relevant dose of the drug heparin. Arch Therapeutics Will Present at the 2014 Aegis Capital Healthcare Conference in Las Vegas, NV September 10-13th, 2014
Marketwire - Tue Sep 02, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
today announced it will be featured as a presenting company at the 2014 Aegis Capital Healthcare Conference. The presentation will take place at 11:25am PDT on Friday, September 12th at The Encore at Wynn in Las Vegas, NV. Arch Therapeutics Will Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
Marketwire - Tue Aug 26, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City. Arch Therapeutics Announces Positive Preclinical Data From Its Study of AC5 Surgical Hemostatic Device(TM) in Animals on Blood Thinner
Marketwire - Mon Aug 25, 6:58AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) for potential use in bleeding during surgery, today announced positive data in an initial preclinical study assessing the use of its AC5 Surgical Hemostatic Device(TM) in animals receiving an anticoagulant medication (i.e. blood thinner). Arch Therapeutics Announces Third Quarter 2014 Results
Marketwire - Wed Aug 06, 6:29AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, today announced financial results for the three and nine months ended June 30, 2014. Arch Therapeutics Announces Collaboration With University College Cork School of Pharmacy
Marketwire - Tue Jul 22, 7:31AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM), has entered into a new collaboration agreement with the University College Cork (UCC) School of Pharmacy in Cork, Ireland, of the National University of Ireland (NUI), focusing on development of hemostasis and sealant products. Arch Therapeutics Selects BSI as Its European Union Notified Body
Marketwire - Tue Jul 15, 7:31AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has selected the British Standards Institution ("BSI" as its Notified Body. A Notified Body is an organization that has been accredited by a member state of the European Union to assess whether a product meets certain preordained standards to receive a CE Mark designation. Arch Therapeutics Appoints Richard Davis as Chief Financial Officer
Marketwire - Mon Jul 07, 5:07PM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has appointed Richard Davis as Chief Financial Officer and Treasurer as it continues to expand its team. Mr. Davis, who has worked as a consultant at Arch since April, has started full time in his new role effective today, July 7, 2014. The Company's current Chief Financial Officer and Treasurer, Alan Barber, has resigned from his position effective July 7, 2014 and has become an advisor to the Company. Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on June 23
Marketwire - Mon Jun 16, 7:15AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announces that co-founder and inventing scientist Dr. Rutledge Ellis-Behnke will present his work using AC5(TM) at the Seventh Annual European Summit for Clinical Nanomedicine and Targeted Medicine in Basel, Switzerland on Monday, June 23. Arch Therapeutics Appoints Chirag Shah, PhD as Vice President of R&D Engineering and Quality Systems and Peter LaCrosse as Chief of Staff
Marketwire - Tue Apr 01, 7:03AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has appointed Chirag Shah, PhD as Vice President of Research and Development Engineering and Quality Systems, effective April 7, 2014, and has appointed Peter A. LaCrosse as Chief of Staff, effective immediately. Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March
Marketwire - Wed Mar 26, 8:03AM CDT
Rutledge Ellis-Behnke, PhD, co-founder and inventing scientist at Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or "the Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, presents his work using AC5(TM) at two scientific meetings. IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:
Arch Therapeutics to Present at The Wall Street Analyst Forum Institutional Investor Conference
Marketwire - Wed Feb 26, 8:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, MD, is scheduled to present a corporate overview at The Wall Street Analyst Forum Conference in Manhattan at The University Club of NYC on Monday, March 3rd at 12:05 PM EST. 10-Q: ARCH THERAPEUTICS, INC.
Edgar Online - Fri Feb 14, 7:42AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Arch Therapeutics Secures $2.85 Million Private Placement
Marketwire - Mon Feb 10, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care has closed a previously announced private placement to accredited individual and institutional investors (the "Investors" . OTC Daily Alert Stock Watch - Arch Therapeutics, Inc. (OTCQB: ARTH)
WorldStockWire - Wed Feb 05, 4:15AM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Arch Therapeutics Announces $2.85 Million Private Placement
Marketwire - Fri Jan 31, 5:00AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce today its private placement to institutional and high net worth investors of an aggregate of 11,400,000 shares of common stock at $0.25 per share, pursuant to the terms of a securities purchase agreement dated January 30, 2014. The private placement is expected to close on or about February 4, 2014, subject to customary closing conditions. Arch Therapeutics Presents 2014 Milestones During Live Webcast
Marketwire - Wed Jan 22, 10:01AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., presented its calendar year 2014 milestone targets during a live audio and high-definition video webcast on Wednesday, January 22 at 10:30AM Eastern Time from the Noble Financial Capital Markets' Tenth Annual Equity Conference in South Florida. Arch Therapeutics to Present Status Update and Milestone Overview at Noble Financial Capital Markets' Tenth Annual Equity Conference
Marketwire - Tue Jan 14, 8:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of the AC5 Surgical Hemostatic Device(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Company CEO, Terrence W. Norchi, M.D., is scheduled to present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference in Sandpiper Bay, Florida, on Wednesday, January 22 at 10:30AM Eastern Time. Arch Therapeutics to Webcast Live From the Biotech Showcase Investor Conference
Marketwire - Wed Jan 08, 8:02AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, a life sciences company and developer of AC5(TM), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that Terrence W. Norchi, M.D., CEO of Arch Therapeutics will present at The Biotech Showcase(TM) 2014 conference on Monday, January 13th, at 5:00PM PST. Attendees will find the presentation scheduled for "Track C" in the Mission II room at that time. Dr. Norchi's presentation will provide insights into the Company's ongoing activities to commercially develop novel technologies into a suite of new products targeting markets of unmet clinical need. 
